ANTIVIRAL COMPOUDS Russian patent published in 2012 - IPC C07D471/04 C07J9/00 A61K31/519 A61K31/575 A61P31/12 

FIELD: pharmacology.

SUBSTANCE: invention refers to the new compounds or its pharmaceutically acceptable salts where the compound has formula I possessing the activity towards hepatitis C virus (HCV). In the compound of formula I, Each W₁ and W₂ means nitrogen, W₃ is chosen out of group consisting of nitrogen and -CH-, and W₄ is -CH-; A is phenyl and is not mandatory substituted, X is chosen out of group consisting out of bond, -O- and -S-, Z is chosen out of group consisting of -CH₂- and -NH-; R²² is chosen out of group consisting of hydrogen, benzimidazole, indole and thiophene, where R²² is not mandatory substituted, Y is chosen out of group consisting of C(O)N(R¹⁵)- and -N(R¹⁵)C(O)-, where R¹⁵ in each case is chosen out of group consisting of hydrogen and C₁-C₆alkyl; R⁵⁰ is -L¹-A¹ where L¹ is chosen out of group consisting of bond and C₁-C₆alkylene, and A¹ is chosen out of group consisting of phenyl, pyridyl, benzothiazolyl, thiadiazole, isothiazole and thiophene, where A¹ is not mandatory replaced, each R¹⁰ and R³⁵ means hydrogen; R¹⁷ is C₁-C₆alkyl; and each C₃-C₁₈carbocyclil and M₃-M₁₈heterocyclil in -L_E-Q-L_E-(C₃-C₁₈carbocyclil) and -L_E-Q-L_E-( M₃-M₁₈heterocyclil) is not mandatory independently substituted in each case.

EFFECT: enhanced cure of hepatitis C.

13 cl, 12 dwg, 459 ex